Switching Imids: The Optimismm Trials Impact On Mm | Latest News RSS feed

Switching Imids: The Optimismm Trials Impact On Mm - Latest News

Celgene (CELG) Q3 2016 Results - Earnings Call Transcript

Furthermore, we are excited about the REVLIMID myeloma data to be presented at ASH this year, including final overall survival data for MM-020 and key analysis ... Our Phase III OPTIMISMM trial in com... read more

Celgene to Present New and Updated Data across a Range of Blood Diseases at EHA 2018

sequencing using data from The Connect ® MM Patient Registry. (Jagannath) Relapsed/Refractory Multiple Myeloma Abstract #S847; Oral; Saturday, June 16, 16:00 – 16:15, Room A1. OPTIMISMM: Phase III tri... read more

Current Challenges in the Management of Patients with Relapsed/Refractory Multiple Myeloma: Page 2 of 2

Impact of prior therapies on the relative efficacy of bortezomib compared with dexamethasone in patients with relapsed/refractory multiple myeloma ... of a phase 2 trial in patients with relapsed and ... read more

Looking for another news?

Lenalidomide for the Treatment of B-Cell Malignancies

Lenalidomide is a novel anticancer agent that has made a major impact ... approved lenalidomide for the treatment of patients with myelodysplastic syndrome with deletion (5q−). However, the activity o... read more

Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma

17 In the MM-003 trial, the proportion of patients treated with pomalidomide plus low-dose dexamethasone who had disease refractory to lenalidomide, bortezomib or both was 95%, 79% and 75%, respective... read more

Dr. Morton Coleman

Dr. Morton Coleman is an oncologist in New York, New York. He received his medical degree from Virginia Commonwealth University School of Medicine and has been in practice for more than 20 years. Onco... read more

Multiple Myeloma

Interaction between Plasma Cells and Bone Marrow in Multiple Myeloma. As part of the interaction between ... 62 A prospective clinical trial is evaluating the effect of delayed transplantation after i... read more

Celgene (CELG) Q2 2017 Results - Earnings Call Transcript

Financial factors, on the other hand, including tax rate, had a negative $0.08 per share impact. OIE was negatively impacted ... Finally, as mentioned on our Q1 call, the Phase III OPTIMISMM trial in ... read more

Dr. David Siegel

Dr. David Siegel is an oncologist in Hackensack, New Jersey and is affiliated with multiple hospitals in the area, including Hackensack University Medical Center and MedStar Georgetown University Hosp... read more

FeedsRSS Created by. Full RSS Feed | Privacy Policy | Contact Us